U.S. Real Estate Stock News

How Ladder Capital Stock Has Been Performing Recently Ladder Capital (LADR) has drawn investor attention after a mixed run in its share price, with the stock down over the year to date but showing gains over the past 3 months and year. This performance sits against reported revenue of $216.26 million and net income of $55.012 million, figures that help frame how the market is currently pricing this US$1.31b real estate investment trust. See our latest analysis for Ladder Capital. The latest...

Coach, part of Tapestry (NYSE:TPR), has launched &Coach, a digital luxury content platform co-created with Gen Z. The platform focuses on social first storytelling and participatory campaigns, with younger creators embedded in the process. &Coach is intended to reshape how the Coach brand builds community and relevance with younger luxury consumers. Tapestry, trading at $145.87, sits behind Coach as its flagship brand and is leaning into a content driven approach to connect with younger...

Tariffs, shifting trade rules, and pressure on global supply chains are reshaping how investors think about US manufacturing stocks. Instead of relying on smooth cross-border trade, markets are reassessing companies that produce more at home and can better control their costs and inputs. This article looks at three US Domestic Manufacturing screener stocks that are directly exposed to these trade headlines and may react in different ways as policies evolve. Each stock is assessed on its...

With Kevin Warsh preparing for his first post-meeting press conference and the Federal Reserve keeping rates at 3.6% while inflation sits at 4.2%, many investors are rethinking how much risk they want to carry. Large-cap defensive stocks, often backed by steady dividends and stronger balance sheets, can look relatively appealing when rate cuts seem less likely and market swings pick up. This article highlights 3 stocks from our Large-Cap Defensive Stocks screener that appear positively...

With the Federal Reserve hinting at possible rate hikes in 2026 and inflation holding at 4.2%, value stocks are back in focus for investors who care about price tags as much as potential. Higher-for-longer rates can reward companies with resilient balance sheets and sensible valuations, while putting pressure on those priced for perfection. This article highlights three value stocks from our screener that are closely exposed to the latest Fed and inflation news. It explains why some investors...

Insider Selling and Valuation Concerns Put Impinj Stock in Focus Impinj (PI) shares fell 5.0% on June 16, 2026, after renewed attention on valuation, with the stock trading 5.5% above its estimated intrinsic value and recent insider selling totaling US$49.4 million. See our latest analysis for Impinj. The latest drop in Impinj's share price fits into a mixed picture, with a 23.29% 90 day share price return contrasting with a year to date share price decline of 31.35%. At the same time, the 5...

If you are wondering whether Corcept Therapeutics stock is still attractively priced after a strong run, the key question now is how its current share price compares with a reasonable view of fair value. The stock last closed at US$81.75, with returns of 4.6% over the past week, 48.3% over the past month, 114.0% year to date, 14.8% over the past year, 264.0% over three years, and 267.3% over five years. These figures naturally raise questions about how much of the story might already be...

Wondering if Yum China Holdings stock still offers value at current levels, or if the recent moves have already priced in the story? This article walks through what the numbers are saying right now. The share price closed at US$43.28, with returns that declined 1.2% over the past week, 4.8% over the past month, and 10.2% year to date. Over longer periods, the share price has risen 3.5% over the past year and declined 20.9% over three years and 30.0% over five years. These shifts can change...

Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress. An additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around...

John Wiley & Sons (WLY) closed FY 2026 with fourth quarter revenue of US$447.9 million and basic EPS of US$2.65, supported by trailing twelve month EPS of US$4.22 on revenue of US$1.68 billion. Over recent periods, the company has seen quarterly revenue move from US$404.6 million in FY 2025 Q3 to US$442.6 million in FY 2025 Q4 and then to US$447.9 million in FY 2026 Q4. Basic EPS shifted from a loss of US$0.43 in FY 2025 Q3 to US$1.27 in FY 2025 Q4 and US$2.65 in FY 2026 Q4, alongside...

PulteGroup (PHM) has drawn investor attention after recent share price moves, with the stock up 13.3% over the past month and 6.6% in the past 3 months, outpacing its shorter term returns. See our latest analysis for PulteGroup. Looking beyond the recent move, PulteGroup’s 1-year total shareholder return of 27.38% and 3-year total shareholder return of 70.49% indicate that the latest share price strength around $124.76 continues a broader period of positive momentum. If you want to see what...

Prosperity Bancshares (PB) stock has drawn attention after recent trading performance, with the shares closing at $71.60. Investors are assessing how the bank's current valuation compares with its profitability and growth profile. See our latest analysis for Prosperity Bancshares. The recent 1 month share price return of 7.67% and 3 month share price return of 11.72% suggest improving momentum for Prosperity Bancshares, while the 1 year total shareholder return of 10.19% points to steadier...

Earlier in 2026, CorMedix Inc. reported strong Q1 results driven by DefenCath and raised its full-year 2026 guidance while outlining progress on late-stage programs such as REZZAYO. Management also emphasized continued business momentum even as the company prepares for the expiration of temporary TDAPA reimbursement, highlighting execution in a changing reimbursement backdrop. Next, we will examine how CorMedix's raised 2026 guidance and DefenCath’s contribution shape the company’s broader...

While Transocean stock trades around US$5.59, you might be wondering whether that price reflects a bargain, a fair deal, or hidden risk in plain sight. Recent returns show a mixed picture, with the share price declining 4.8% over the past week and 20.6% over the past month, yet still up 31.8% year to date and 74.1% over the past year. These moves sit against a backdrop of ongoing interest in offshore drilling and changing sentiment around energy services stocks, which can quickly reshape how...

Ardelyx (ARDX) is back in focus after recent trading, with the stock closing at $5.67 and showing mixed short term performance, including a decline over the past month and a gain over the past 3 months. See our latest analysis for Ardelyx. Looking beyond the latest move, Ardelyx’s share price return is down over the past month but slightly up over the past quarter, while its 1 year total shareholder return is strongly positive. This suggests earlier optimism is being reassessed rather than...

Allison Transmission Holdings (NYSE:ALSN) secured a record US$250 million contract to supply its advanced 4040 MX transmissions for BAE Systems’ CV90 MkIV tracked defense vehicles. The agreement is described as the largest tracked defense program deal in Allison Transmission’s history. The 4040 MX transmission will move from development into a full production platform under this contract, with deliveries scheduled to begin in 2028 after integration testing with BAE. For investors following...

10x Genomics (NasdaqGS:TXG) announced a multi-year research collaboration with Cleveland Clinic focused on bladder cancer diagnostics. The partnership centers on using single-cell, spatial transcriptomic, and protein profiling technologies to build multimodal cancer datasets. The collaborators plan to link molecular data with clinical outcomes, aiming to support future diagnostic applications across oncology. 10x Genomics enters this Cleveland Clinic collaboration with its stock at $31.75...

Citizens Financial Group (NYSE:CFG) has appointed Chris Emerson as Head of Investor Relations, while he continues to lead Corporate Planning and Enterprise Finance. Kristin Silberberg is moving into the role of Chief Financial Officer of the Commercial Bank. These leadership changes place new executives in key financial and investor-facing positions at the company. Citizens Financial Group enters these leadership shifts with NYSE:CFG trading at $67.27. Over the past year, the stock is up...

If you are wondering whether Park Hotels & Resorts stock still offers value at around US$14.69, the key question is how its current price compares with what the business might reasonably be worth. The stock has returned 3.8% over the past week, 36.5% over the last month, 36.4% year to date, 58.3% over the last year, 64.2% over three years and 0.1% over five years, which can change how investors think about both upside potential and risk. Recent news coverage around Park Hotels & Resorts has...

CRH plc recently announced that former CF Industries CEO Tony Will, an experienced industrial and board leader with a background across manufacturing, consulting and transportation, will join its Board of Directors effective July 1, 2026. His blend of heavy-industry operating experience and current role on Union Pacific’s board adds expertise in large-scale capital allocation, logistics and governance that could influence CRH’s long-term decision-making. We’ll now examine how Tony Will’s...

The United States market has experienced a 2.3% increase over the last week and a significant 25% rise in the past year, with earnings projected to grow by 19% annually. In such an environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation amidst robust market growth.

Over the last 7 days, the United States market has risen by 2.3%, contributing to a robust 25% increase over the past year, with earnings forecasted to grow by 19% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for future success.

The United States market has experienced a robust climb, with a 2.3% increase in the last week and a significant 25% rise over the past year, while earnings are projected to grow by 19% annually. Amidst these favorable conditions, identifying stocks that combine affordability with growth potential is key, especially when considering penny stocks. Although the term 'penny stock' might seem outdated, these smaller or newer companies can still offer substantial opportunities for investors who...

US manufacturing stocks are back in focus as fresh tariff proposals, trade investigations, and the prospect of a new US-China Board of Trade reshape expectations for supply chains and costs. For investors, the question is which US Domestic Manufacturing Stocks could potentially benefit from this policy turn and which might face pressure as trade relationships evolve. This article highlights 3 stocks from the screener that are directly exposed to these trade headlines, explaining how the same...